HUP0204023A2 - Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0204023A2 HUP0204023A2 HU0204023A HUP0204023A HUP0204023A2 HU P0204023 A2 HUP0204023 A2 HU P0204023A2 HU 0204023 A HU0204023 A HU 0204023A HU P0204023 A HUP0204023 A HU P0204023A HU P0204023 A2 HUP0204023 A2 HU P0204023A2
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- combination
- pharmaceutical compositions
- compositions containing
- cns disorders
- Prior art date
Links
- LBTUTDYXOOUODJ-UHFFFAOYSA-N 2-pyrrolidin-1-ylacetamide Chemical class NC(=O)CN1CCCC1 LBTUTDYXOOUODJ-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 abstract 3
- 229960004002 levetiracetam Drugs 0.000 abstract 3
- 208000020925 Bipolar disease Diseases 0.000 abstract 2
- 208000000094 Chronic Pain Diseases 0.000 abstract 2
- 206010026749 Mania Diseases 0.000 abstract 2
- 208000019695 Migraine disease Diseases 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 206010027599 migraine Diseases 0.000 abstract 2
- 208000004296 neuralgia Diseases 0.000 abstract 2
- 208000021722 neuropathic pain Diseases 0.000 abstract 2
- 102000027484 GABAA receptors Human genes 0.000 abstract 1
- 108091008681 GABAA receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Abstract
A találmány tárgya (I) képletű levetiracetam alkalmazása bipoláriszavarok, mánia, migrén és krónikus és neuropathiás fájdalom kezeléséreszolgáló gyógyszer előállítására. A találmány tárgyát képezi továbbágyógyászati készítmény bipoláris zavarok, mánia, migrén és krónikus ésneuropathiás fájdalom kezelésére, amely levetiracetam terápiásanhatékony mennyiségét és egy gyógyászatilag alkalmazható vivőanyagottartalmaz, illetve levetiracetam tartalmú gyógyászati készítményalkalmazása olyan páciens kezelésére szolgáló gyógyszer előállítására,akinek legalább egy GABAA receptorok mediálta neurális gátlástindukáló vegyületet adagolnak olyan mennyiségben, ami önmagában advanem lenne terápiásan hatékony. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99123803 | 1999-12-01 | ||
EP99124269 | 1999-12-01 | ||
PCT/EP2000/011808 WO2001039779A1 (en) | 1999-12-01 | 2000-11-27 | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0204023A2 true HUP0204023A2 (hu) | 2003-03-28 |
HUP0204023A3 HUP0204023A3 (en) | 2005-03-29 |
Family
ID=26153183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0204023A HUP0204023A3 (en) | 1999-12-01 | 2000-11-27 | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders and pharmaceutical compositions containing them |
Country Status (32)
Country | Link |
---|---|
US (2) | US6903130B1 (hu) |
EP (4) | EP1600169A3 (hu) |
JP (2) | JP4249415B2 (hu) |
KR (1) | KR20030016205A (hu) |
CN (1) | CN100525761C (hu) |
AR (1) | AR026610A1 (hu) |
AT (1) | ATE361751T1 (hu) |
AU (1) | AU773418B2 (hu) |
BG (1) | BG106708A (hu) |
BR (1) | BR0015974A (hu) |
CA (2) | CA2475026A1 (hu) |
CO (1) | CO5261590A1 (hu) |
CZ (1) | CZ20021904A3 (hu) |
DE (1) | DE60034815T2 (hu) |
EE (1) | EE200200274A (hu) |
ES (1) | ES2287039T3 (hu) |
HK (1) | HK1052647B (hu) |
HU (1) | HUP0204023A3 (hu) |
IL (2) | IL149530A0 (hu) |
IS (1) | IS6377A (hu) |
MX (1) | MXPA02005275A (hu) |
MY (1) | MY127980A (hu) |
NO (1) | NO20022585L (hu) |
NZ (1) | NZ518901A (hu) |
PL (1) | PL357472A1 (hu) |
RO (1) | RO121085B1 (hu) |
RU (1) | RU2261093C2 (hu) |
SA (1) | SA01210655B1 (hu) |
SK (1) | SK7492002A3 (hu) |
TW (1) | TWI238062B (hu) |
WO (1) | WO2001039779A1 (hu) |
YU (1) | YU37602A (hu) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
US7683071B2 (en) | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
US6756379B2 (en) | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
CA2433039C (en) | 2000-12-28 | 2010-06-08 | Daiichi Pharmaceutical Co., Ltd. | Agent for therapeutic and prophylactic treatment of neuropathic pain |
CA2438930A1 (en) * | 2001-02-23 | 2002-09-06 | Johns Hopkins University | Treatment of tics, tremors and related disorders |
AU2002344820B2 (en) * | 2001-06-20 | 2006-12-14 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
US7544681B2 (en) | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
CA2461961A1 (en) * | 2001-10-08 | 2003-04-17 | Ucb, S.A. | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders |
AU2003242538A1 (en) * | 2002-05-14 | 2003-11-11 | Ucb, S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug |
US20070135514A1 (en) * | 2002-12-03 | 2007-06-14 | Berkley Lynch | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
CA2505335C (en) | 2002-12-11 | 2013-09-10 | Daniel Aaron Moros | Method of treating movement disorders using barbituric acid derivatives |
WO2004083180A1 (en) * | 2003-03-18 | 2004-09-30 | Hetero Drugs Limited | Novel crystalline forms of levetiracetam |
GB0307860D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Organic compounds |
WO2004093910A1 (ja) * | 2003-04-22 | 2004-11-04 | Astellas Pharma Inc. | PPARδアゴニストによる脳神経変性疾患治療剤 |
JP4715514B2 (ja) * | 2003-10-03 | 2011-07-06 | 小野薬品工業株式会社 | 神経再生促進剤 |
EP1871363A4 (en) * | 2005-03-30 | 2009-01-21 | Genpharm Inc | COMBINED STAGE PROCESS FOR PHARMACEUTICAL COMPOSITIONS |
US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
WO2006127300A1 (en) * | 2005-05-24 | 2006-11-30 | Cambrex Charles City, Inc. | SYNTHESIS OF (S)-α-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE |
CN101068534B (zh) | 2005-07-26 | 2011-09-07 | Ucb医药有限公司 | 包括左乙拉西坦的药物组合物及其制备方法 |
US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
FR2890563B1 (fr) * | 2005-09-09 | 2007-10-19 | Servier Lab | Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent |
CA2637925A1 (en) * | 2006-01-24 | 2007-08-02 | Teva Pharmaceutical Industries Ltd. | Levetiracetam formulations and methods for their manufacture |
WO2007144195A2 (en) * | 2006-06-15 | 2007-12-21 | Schwarz Pharma Ag | Pharmaceutical composition with synergistic anticonvulsant effect |
CN101511388B (zh) * | 2006-07-17 | 2012-10-24 | 特拉维夫大学拉莫特有限公司 | 含有精神药物或gaba激动剂和有机酸的缀合物以及它们在治疗疼痛和其它cns疾病中的用途 |
GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
AU2007346591A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of ADHD |
ITMI20070770A1 (it) * | 2007-04-16 | 2008-10-17 | Brane Discovery S R L | Impiego di dimiracetam nel trattamento del dolore cronico |
AU2012201853B2 (en) * | 2007-04-16 | 2013-06-27 | Neurotune Ag | Use of dimiracetam in the treatment of chronic pain |
US8207369B2 (en) | 2008-02-11 | 2012-06-26 | Ramot At Tel-Aviv University Ltd. | Conjugates for treating neurodegenerative diseases and disorders |
CN102170874A (zh) | 2008-08-06 | 2011-08-31 | 高思福斯中心(控股)有限公司 | 治疗精神病学障碍的组合物和方法 |
AU2009303834B2 (en) | 2008-10-16 | 2016-08-11 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
PL389364A1 (pl) * | 2009-10-23 | 2011-04-26 | Uniwersytet Jagielloński | Nowe zastosowanie pochodnych 2-pirolidonu |
WO2011104637A2 (en) | 2010-02-24 | 2011-09-01 | Ramot At Tel-Aviv University Ltd. | Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same |
US8822539B2 (en) * | 2010-03-28 | 2014-09-02 | Children's Medical Center Corporation | Combination therapies: inhibitors of GABA transaminase and NKCC1 |
WO2012038963A1 (en) | 2010-09-22 | 2012-03-29 | Ramot At Tel-Aviv University Ltd. | An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same |
AU2018208662B2 (en) * | 2012-11-14 | 2020-07-23 | The Johns Hopkins University | Methods and Compositions for Treating Schizophrenia |
JP6440625B2 (ja) * | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
WO2014144801A1 (en) | 2013-03-15 | 2014-09-18 | Agenebio Inc. | Methods and compositions for improving cognitive function |
EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
KR101690175B1 (ko) * | 2013-07-02 | 2016-12-27 | 경희대학교 산학협력단 | 고본 추출물을 유효성분으로 포함하는 불면증의 예방 또는 치료용 약학적 조성물 |
RU2538724C1 (ru) * | 2013-12-19 | 2015-01-10 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Способ лечения эпилепсии |
NZ722385A (en) | 2014-01-21 | 2019-11-29 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
UA127921C2 (uk) * | 2014-01-21 | 2024-02-14 | Янссен Фармацевтика Нв | Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування |
RU2563124C1 (ru) * | 2014-04-28 | 2015-09-20 | Федеральное государственное бюджетное учреждение "Федеральный медицинский исследовательский центр психиатрии и наркологии имени В.П. Сербского" Министерства здравоохранения Российской Федерации (ФГБУ "ФМИЦПН им. В.П. Сербского" Минздрава России) | Способ диагностики шизофрении |
BR112017025031B1 (pt) | 2015-05-22 | 2023-03-21 | Agenebio, Inc | Composições farmacêuticas de liberação prolongada de levetiracetam |
AU2017341927B2 (en) * | 2016-10-14 | 2021-12-16 | CNS Biosciences, Inc. | Treating neuropathic pain in spinal cord injured individuals |
PL244071B1 (pl) * | 2019-01-07 | 2023-11-27 | Univ Jagiellonski | Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8412357D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
GB8827389D0 (en) | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
EP0408782A1 (en) | 1989-07-18 | 1991-01-23 | Nauchnoissledovatelski Chimikopharmatzevtichen Institut | Antihypoxic agent |
GB9319732D0 (en) | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
US5998380A (en) * | 1995-10-13 | 1999-12-07 | New England Medical Center Hospitals, Inc. | Treatment of migraine |
HUP0004439A3 (en) | 1997-12-16 | 2001-12-28 | Warner Lambert Co | 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
AU2463099A (en) | 1998-01-23 | 1999-08-09 | Warner-Lambert Company | Gabapentin and its derivatives for the treatment of muscular and skeletal pain |
DE19820381B4 (de) * | 1998-05-07 | 2007-01-25 | Trw Fahrwerksysteme Gmbh & Co Kg | Verfahren zur Beeinflussung der Ventilkennlinie |
US6495601B1 (en) | 1998-12-23 | 2002-12-17 | Cytoscan Sciences Llc | Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms |
EP1141251A4 (en) * | 1998-12-23 | 2004-09-22 | Cytoscan Sciences Llc | COMPOSITIONS, SCREENING TECHNIQUES AND METHODS FOR TREATING DISORDERS OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS |
SK286104B6 (sk) * | 1999-07-01 | 2008-03-05 | Pharmacia & Upjohn Company | Použitie (S,S) reboxetínu na prípravu lieku na liečenie alebo prevenciu chronickej bolesti |
AU2003225813A1 (en) * | 2002-03-18 | 2003-10-08 | Roger K. Cady | Preemptive prophylaxis of migraine |
US20040116506A1 (en) * | 2002-06-20 | 2004-06-17 | Krusz John Claude | Use of levetiracetam for treating or preventing acute headaches |
US20070135514A1 (en) * | 2002-12-03 | 2007-06-14 | Berkley Lynch | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
-
2000
- 2000-11-27 WO PCT/EP2000/011808 patent/WO2001039779A1/en active IP Right Grant
- 2000-11-27 EP EP05019212A patent/EP1600169A3/en not_active Withdrawn
- 2000-11-27 BR BR0015974-3A patent/BR0015974A/pt not_active Application Discontinuation
- 2000-11-27 AU AU15241/01A patent/AU773418B2/en not_active Ceased
- 2000-11-27 PL PL00357472A patent/PL357472A1/xx unknown
- 2000-11-27 CA CA002475026A patent/CA2475026A1/en not_active Abandoned
- 2000-11-27 NZ NZ518901A patent/NZ518901A/en unknown
- 2000-11-27 TW TW089125114A patent/TWI238062B/zh not_active IP Right Cessation
- 2000-11-27 ES ES00977580T patent/ES2287039T3/es not_active Expired - Lifetime
- 2000-11-27 CN CNB008165378A patent/CN100525761C/zh not_active Expired - Fee Related
- 2000-11-27 YU YU37602A patent/YU37602A/sh unknown
- 2000-11-27 RO ROA200200730A patent/RO121085B1/ro unknown
- 2000-11-27 EP EP00977580A patent/EP1244456B1/en not_active Expired - Lifetime
- 2000-11-27 IL IL14953000A patent/IL149530A0/xx active IP Right Grant
- 2000-11-27 SK SK749-2002A patent/SK7492002A3/sk unknown
- 2000-11-27 KR KR1020027006987A patent/KR20030016205A/ko not_active Application Discontinuation
- 2000-11-27 EE EEP200200274A patent/EE200200274A/xx unknown
- 2000-11-27 EP EP05019211A patent/EP1600168A3/en not_active Withdrawn
- 2000-11-27 JP JP2001541511A patent/JP4249415B2/ja not_active Expired - Fee Related
- 2000-11-27 EP EP05019209A patent/EP1600167A3/en not_active Withdrawn
- 2000-11-27 AT AT00977580T patent/ATE361751T1/de not_active IP Right Cessation
- 2000-11-27 HU HU0204023A patent/HUP0204023A3/hu unknown
- 2000-11-27 AR ARP000106224A patent/AR026610A1/es unknown
- 2000-11-27 DE DE60034815T patent/DE60034815T2/de not_active Expired - Lifetime
- 2000-11-27 US US10/148,347 patent/US6903130B1/en not_active Expired - Fee Related
- 2000-11-27 RU RU2002117279/15A patent/RU2261093C2/ru not_active IP Right Cessation
- 2000-11-27 CA CA002392879A patent/CA2392879C/en not_active Expired - Fee Related
- 2000-11-27 CZ CZ20021904A patent/CZ20021904A3/cs unknown
- 2000-11-27 MX MXPA02005275A patent/MXPA02005275A/es active IP Right Grant
- 2000-11-30 CO CO00091771A patent/CO5261590A1/es not_active Application Discontinuation
- 2000-12-01 MY MYPI20005634A patent/MY127980A/en unknown
-
2001
- 2001-01-20 SA SA01210655A patent/SA01210655B1/ar unknown
-
2002
- 2002-05-08 IL IL149530A patent/IL149530A/en not_active IP Right Cessation
- 2002-05-10 IS IS6377A patent/IS6377A/is unknown
- 2002-05-16 BG BG106708A patent/BG106708A/bg unknown
- 2002-05-31 NO NO20022585A patent/NO20022585L/no not_active Application Discontinuation
-
2003
- 2003-07-09 HK HK03104923.1A patent/HK1052647B/zh not_active IP Right Cessation
-
2005
- 2005-04-21 US US11/111,636 patent/US20050187205A1/en not_active Abandoned
-
2007
- 2007-11-14 JP JP2007295865A patent/JP2008056697A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0204023A2 (hu) | Pirrolidinacetamidszármazék alkalmazása önmagában vagy kombinációban központi idegrendszeri zavarok kezelésére és ezeket tartalmazó gyógyszerkészítmények | |
BG105005A (en) | Pyrazoline derivatives, their preparation and application as medicaments | |
HUP0203325A2 (hu) | Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
GEP20053595B (en) | Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment | |
HUP0302474A2 (hu) | Terápiásan hatásos tropánszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
SE0104340D0 (sv) | New compounds | |
MY129422A (en) | Medicinal compounds | |
TR200002207T1 (tr) | Slekoksib bileşikleri. | |
BG104727A (en) | Pharmaceutical composition of topiramate | |
ES2165969T3 (es) | Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios. | |
HUP0003351A2 (hu) | 2-Szubsztituált-4,5-diaril-imidazolok, eljárás e vegyületek előállítására, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
HUP0103542A2 (hu) | Opioid-receptor aktivitással rendelkező 4,4-biaril-piperidin származékok és a vegyületeket tartalmazó gyógyászati készítmények | |
NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
CA2241904A1 (en) | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | |
ATE282418T1 (de) | Orale verabreichung wirksamer mengen von hyaluronsäure | |
ES2193875A1 (es) | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. | |
RU2007104774A (ru) | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы | |
SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors | |
HUP0302068A2 (hu) | COX-2 inhibitorok alkalmazása immundeficienciával járó rendellenességek kezelésére vagy megelőzésére és ezeket tartalmazó gyógyszerkészítmények | |
ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
AU2002359162A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
PL370529A1 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug | |
HUP0402577A2 (hu) | Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra | |
YU84503A (sh) | Upotreba azitromicina za pripremanje leka za lečenje neinfektivnih inflamatornih oboljenja | |
NZ767378A (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |